Neurizon Secures Note Reduction and Share Sale Standstill
Neurizon will redeem 1 million convertible notes held by Obsidian for US$1.15 million, while securing a two-month standstill on share sales. The biotechnology company says the transaction leaves it funded through the HEALEY ALS trial readout and completion.
- US$1.15 million redemption of 1 million convertible notes
- Obsidian’s holding falls to 750,000 notes
- Two-month restriction on Neurizon share sales
- Company says trial funding remains secured
Neurizon Reduces Obsidian Note Holding
Neurizon Therapeutics Limited (ASX:NUZ; OTCQB: NUZTF) is paying US$1.15 million to redeem 1 million convertible notes held by Obsidian, cutting Obsidian’s remaining holding to 750,000 notes. The notes have a face value of US$1.11 million, meaning the agreed consideration includes a US$40,000 premium to face value.
The transaction also comes with a two-month agreement by Obsidian not to sell Neurizon shares. That standstill gives the company a temporary measure against potential selling pressure, although the announcement does not specify the settlement date, the conversion terms attached to the remaining notes, or the eventual dilution those securities could create.
Funding Claim Rests on Trial Runway
Neurizon says it remains fully funded through the topline readout and completion of the Phase 2/3 HEALEY ALS Platform Trial, which is evaluating its investigational NUZ-001 candidate for amyotrophic lateral sclerosis. The statement is management’s position in this announcement; it is not accompanied by an updated cash balance, forecast or detailed funding schedule.
The board described the redemption as part of an active approach to capital management and said it would continue reviewing the company’s funding structure. Interim executive chairman Sergio Duchini said the improved premium and share-sale standstill represented an appropriate allocation of shareholder funds, without providing further financial detail.
Remaining Convertible Exposure Matters
Obsidian was originally issued 3,575,500 convertible notes under a December 2025 Convertible Securities and Security Placement Agreement. The partial redemption therefore removes a substantial portion of that original holding, but does not eliminate the company’s exposure to future conversion or dilution from the 750,000 notes that remain.
The immediate question is whether the agreed redemption completes as planned and how the remaining notes are ultimately dealt with. Neurizon’s next funding update, alongside progress towards the HEALEY readout, will test whether the stated runway is sufficient without another capital event before the trial reaches its next decisive milestone.
Bottom Line?
The deal lowers Obsidian’s convertible note position and buys a short-term share-sale standstill, but the remaining notes and Neurizon’s unsupported funding assertion remain key points to track.
Questions in the middle?
- When will the US$1.15 million redemption formally settle?
- What conversion or dilution risk remains from the 750,000 outstanding notes?
- Can Neurizon complete the HEALEY trial without requiring additional capital?
